EMAW began with a mission to
revolutionize real-world data collection Ecological Momentary Assessments and wearable/sensor technologies
Early on, we recognized the power of remote, patient-centric insights to transform clinical research.
Just before the pandemic, sponsor partners challenged us to expand beyond EMAs—asking for a seamless way to capture eCOA (electronic Clinical Outcome Assessments) and digital biomarkers alongside wearable data. Thanks to our agile, purpose-built architecture, adding these capabilities was technologically simple and highly scalable. This flexibility allowed us to deliver a cost-effective, unified solution at a time when the industry needed it most.
Today:
Leading Neuropsychiatric TrialsEMAW’s platform now powers Phase 2 and 3 neuropsychiatric trials, trusted for its unique ability to combine:
Over 25+
Countries
Speed
Rapid deployment of eCOA, EMA, and sensor tools.
Configurability
Tailored workflows for in-clinic, hybrid, or fully remote designs.
Adjudication
Built-in quality control for regulatory-grade data.